These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 22596253)

  • 21. Neuropeptide families: an evolutionary perspective.
    Sherwood NM; Parker DB
    J Exp Zool Suppl; 1990; 4():63-71. PubMed ID: 1974805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinetic Profile of Neuropeptide-Receptor Interactions.
    Nederpelt I; Bunnik J; IJzerman AP; Heitman LH
    Trends Neurosci; 2016 Dec; 39(12):830-839. PubMed ID: 27793433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The CRF peptide family and their receptors: yet more partners discovered.
    Dautzenberg FM; Hauger RL
    Trends Pharmacol Sci; 2002 Feb; 23(2):71-7. PubMed ID: 11830263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics.
    Mathew SJ; Price RB; Charney DS
    Am J Med Genet C Semin Med Genet; 2008 May; 148C(2):89-98. PubMed ID: 18412102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of apelin on hypothalamic-pituitary-adrenal axis neuroendocrine function are mediated through corticotrophin-releasing factor- and vasopressin-dependent mechanisms.
    Newson MJ; Roberts EM; Pope GR; Lolait SJ; O'Carroll AM
    J Endocrinol; 2009 Jul; 202(1):123-9. PubMed ID: 19395447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of corticotropin-releasing factor in drug addiction: potential for pharmacological intervention.
    Logrip ML; Koob GF; Zorrilla EP
    CNS Drugs; 2011 Apr; 25(4):271-87. PubMed ID: 21425881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular evolution of neuropeptide receptors with regard to maintaining high affinity to their authentic ligands.
    Cho HJ; Acharjee S; Moon MJ; Oh DY; Vaudry H; Kwon HB; Seong JY
    Gen Comp Endocrinol; 2007; 153(1-3):98-107. PubMed ID: 17286976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mimicking of Arginine by Functionalized N(ω)-Carbamoylated Arginine As a New Broadly Applicable Approach to Labeled Bioactive Peptides: High Affinity Angiotensin, Neuropeptide Y, Neuropeptide FF, and Neurotensin Receptor Ligands As Examples.
    Keller M; Kuhn KK; Einsiedel J; Hübner H; Biselli S; Mollereau C; Wifling D; Svobodová J; Bernhardt G; Cabrele C; Vanderheyden PM; Gmeiner P; Buschauer A
    J Med Chem; 2016 Mar; 59(5):1925-45. PubMed ID: 26824643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tachykinins and tachykinin receptors: structure and activity relationships.
    Almeida TA; Rojo J; Nieto PM; Pinto FM; Hernandez M; Martín JD; Candenas ML
    Curr Med Chem; 2004 Aug; 11(15):2045-81. PubMed ID: 15279567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurotensin and neurotensin receptors.
    Vincent JP; Mazella J; Kitabgi P
    Trends Pharmacol Sci; 1999 Jul; 20(7):302-9. PubMed ID: 10390649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Corticotropin-releasing factor antagonists: recent advances and exciting prospects for the treatment of human diseases.
    Gilligan PJ; Li YW
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):487-97. PubMed ID: 15338958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Vasopressin receptors: structure/function relationships and signal transduction in target cells].
    Robert J; Clauser ER
    J Soc Biol; 2005; 199(4):351-9. PubMed ID: 16738530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The mammalian tachykinin receptors.
    Maggi CA
    Gen Pharmacol; 1995 Sep; 26(5):911-44. PubMed ID: 7557266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A neurotensin receptor antagonist inhibits acute immobilization stress-induced cardiac mast cell degranulation, a corticotropin-releasing hormone-dependent process.
    Pang X; Alexacos N; Letourneau R; Seretakis D; Gao W; Boucher W; Cochrane DE; Theoharides TC
    J Pharmacol Exp Ther; 1998 Oct; 287(1):307-14. PubMed ID: 9765351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Cholecystokinin receptors. A target for tomorrow's psychopharmaceuticals?].
    Zachrisson O; Lindefors N
    Lakartidningen; 1996 Mar; 93(13):1225-7. PubMed ID: 8656838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The corticotropin-releasing factor system as a potential target for antiobesity drugs.
    Doyon C; Moraru A; Richard D
    Drug News Perspect; 2004 Oct; 17(8):505-17. PubMed ID: 15605110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The corticotropin-releasing factor family of peptides and CRF receptors: their roles in the regulation of energy balance.
    Richard D; Lin Q; Timofeeva E
    Eur J Pharmacol; 2002 Apr; 440(2-3):189-97. PubMed ID: 12007535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The central vasopressinergic system: examining the opportunities for psychiatric drug development.
    Ring RH
    Curr Pharm Des; 2005; 11(2):205-25. PubMed ID: 15638758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of neuropeptide B on feeding behavior is influenced by endogenous corticotropin-releasing factor activities.
    Aikawa S; Ishii M; Yanagisawa M; Sakakibara Y; Sakurai T
    Regul Pept; 2008 Nov; 151(1-3):147-52. PubMed ID: 18760311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The CRF System as a Therapeutic Target for Neuropsychiatric Disorders.
    Sanders J; Nemeroff C
    Trends Pharmacol Sci; 2016 Dec; 37(12):1045-1054. PubMed ID: 27717506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.